ریمگپنت (Rimegepant) (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "ریمگپنت (Rimegepant)" in Persian language version.

refsWebsite

Global rank Persian rank

13web.archive.org

1^st place

3tga.gov.au

3,984^th place

1,143^rd place

3nih.gov

4^th place

5^th place

3fda.gov

447^th place

382^nd place

2europa.eu

68^th place

179^th place

1hres.ca

low place

1canada.ca

1,712^th place

2,923^rd place

1hpfb-dgpsa.ca

low place

1doi.org

2^nd place

1prnewswire.com

406^th place

1,024^th place

canada.ca

"Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28]". Health Canada. 28 February 2024. Archived from the original on 2 March 2024. Retrieved 2 March 2024.

doi.org

Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–1022. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.

europa.eu

ema.europa.eu

"Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 16 October 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022.

fda.gov

"Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «FDA snapshot» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020.

accessdata.fda.gov

"Drug Approval Package: Nurtec ODT". U.S. Food and Drug Administration (FDA). 26 March 2020. Archived from the original on 27 December 2021. Retrieved 16 October 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Drug Approval Package: Nurtec ODT» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Nurtec ODT". Health Canada. 1 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.

hres.ca

pdf.hres.ca

"Archived copy" (PDF). Archived (PDF) from the original on 3 March 2024. Retrieved 10 March 2024.{{cite web}}: نگهداری یادکرد:عنوان آرشیو به جای عنوان (link)

nih.gov

dailymed.nlm.nih.gov

"Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
"Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.

pubmed.ncbi.nlm.nih.gov

Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–1022. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.

prnewswire.com

"Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020. Archived from the original on 26 July 2021. Retrieved 28 February 2020.

tga.gov.au

"Nurtec ODT". Therapeutic Goods Administration (TGA). 8 August 2023. Archived from the original on 11 October 2023. Retrieved 10 September 2023.
https://www.tga.gov.au/resources/auspar/auspar-nurtec-odt
"Nurtec ODT (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 22 August 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.

web.archive.org

"Nurtec ODT". Therapeutic Goods Administration (TGA). 8 August 2023. Archived from the original on 11 October 2023. Retrieved 10 September 2023.
"Nurtec ODT (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 22 August 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.
"Archived copy" (PDF). Archived (PDF) from the original on 3 March 2024. Retrieved 10 March 2024.{{cite web}}: نگهداری یادکرد:عنوان آرشیو به جای عنوان (link)
"Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28]". Health Canada. 28 February 2024. Archived from the original on 2 March 2024. Retrieved 2 March 2024.
"Details for: Nurtec ODT". Health Canada. 1 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
"Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
"Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 16 October 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «FDA snapshot» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Drug Approval Package: Nurtec ODT". U.S. Food and Drug Administration (FDA). 26 March 2020. Archived from the original on 27 December 2021. Retrieved 16 October 2022. خطای یادکرد: برچسب <ref> نامعتبر؛ نام «Drug Approval Package: Nurtec ODT» چندین بار با محتوای متفاوت تعریف شده است. (صفحهٔ راهنما را مطالعه کنید.).
"Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
"Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020.
"Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020. Archived from the original on 26 July 2021. Retrieved 28 February 2020.
"Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022.